权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Assessing the interferome in novel, purpose-driven bat-derived cells

评估新型、目的驱动的蝙蝠来源细胞中的干扰素

基本信息

批准号：
10569631
负责人：
Arinjay Banerjee
金额：
$ 19.18万
依托单位：
WASHINGTON STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-02-09 至 2025-01-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10569631
关键词：
2019-nCoV Agriculture Animals Biological Assay Brain Breeding Cell Culture Techniques Cell Line Cells Chiroptera Clinical Collection Communities Comparative Study Competence Complement Receptor Coronavirus Critical Pathways Data Development Disease Feasibility Studies Future Genus Pteropus Goals Human Immunologics Immunology Infection Infection Control Innate Immune Response Interferon Type I Interferons Kidney Knowledge Laboratories Liver Lung Mediating Middle East Respiratory Syndrome Coronavirus Modeling Molecular Natural Immunity Nipah Virus Pathway interactions Poly I-C Predisposition Primary Cell Cultures Process RNA Viruses Reagent Recombinant Cytokines Recombinant Interferon Recombinants Reporter Research Research Personnel Resistance Rousettus SARS coronavirus Sendai virus Spleen Testing Therapeutic Tissues Tropism Vesicular stomatitis Indiana virus Viral Virus Virus Diseases Virus Receptors Virus Replication Zoonoses antiviral immunity bat-borne betacoronavirus cell culture collection cell immortalization cell type cytokine experience global health in vitro Model in vivo innate immune pathways new therapeutic target novel novel therapeutics particle pathogen pathogenic virus permissiveness public repository response tool translational study

项目摘要

Assessing the interferome of novel, purpose-driven bat-derived cells SUMMARY/ABSTRACT Over the last decade, bats have emerged as intriguing mammalian reservoirs of emerging high impact viruses that cause severe disease in humans and agricultural animals. However, bats that are naturally or experimentally infected with these viruses do not develop clinical signs of disease. Thus, understanding how bats tolerate virus infections may allow us to develop novel drugs or identify new drug targets for alternate mammalian species, such as humans. In spite of recent advances in bat immunology, studies have largely relied on cell culture models from selected bat species, limiting our understanding of this diverse mammalian order. The order Chiroptera is made up of over 1420 species of bats, and data from a handful of bats do not represent evolutionary adaptations in all bats. In addition, these reagents are not available on public repositories making it hard for the research community to pursue this intriguing and growing field of research. For our proposal, we propose to develop novel bat reagents, including primary and immortalized cells from five major bat species, Rousettus aegyptiacus, Pteropus alecto, Eptesicus fuscus, Artibeus jamaicensis, and Carollia perspicillata, representing bats that currently exist in research colonies, making future in vivo translational studies feasible and logical. Data from selected bats, such as Rousettus, Pteropus and Eptesicus bats suggest that bat cells have evolved adaptations in their cytokine responses to better tolerate virus infections relative to humans. Type I interferon (IFN) responses are the first line of mammalian antiviral defense, and although type I IFNs and their downstream effects have been studied in selected bat cells, global cellular responses and the full range of IFN-mediated antiviral effects or the ‘interferome’ remain elusive. For this project, we shall use our diverse bat cell types, derived from multiple bat species, to identify and delineate evolutionarily conserved and unique bat-specific IFN responses. Results from our study will shed light on intriguing questions around the ability of bats to control infection with zoonotic RNA viruses, along with making important discoveries on evolutionary adaptations in the mammalian type I IFN pathway. Importantly, our research will generate critical bat reagents, such as primary cells, cell lines, recombinant cytokines and molecular assays that will facilitate the development of larger collaborative projects to study bat immunology.

评估新型，目的驱动的蝙蝠来源细胞的干扰素